Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
On June 6, 2003, the Court of Appeals for the Federal Circuit seemingly breathed new life into research tool patents when it held that the use of patented peptides for drug discovery was not exempt from infringement under the “safe harbor” provision of 35 U.S.C. '271(e)(1). Integra Lifesciences, Ltd. v. Merck KGaA, 331 F.3d 860 (Fed. Cir. 2003). In an earlier case, Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer, Inc., No. 95 Civ. 8833, 2001 WL 1512597 (S.D.N.Y 2001), a district court had ruled that the use of patented intermediates for drug screening was non-infringing, thereby implicating that the use of other research tool patents for drug discovery was likewise sheltered from infringement liability under '271(e)(1).
The Bristol-Myers district court decision had raised questions in the industry about the value and enforceability of research tool patents. The Federal Circuit's decision in Integra provides patentees with some indication that their patents can be enforced against at least pre-clinical drug discovery uses of the research tools.
However, in resurrecting research tool patents, the Federal Circuit determined that the jury's reasonable royalty damages award of $15 million was not supported by the evidence and remanded for further considerations. Accordingly, in deciding whether to litigate or license research tool patents (or to pursue patent protection in the first instance), patent owners and research tool users will want to carefully consider the value of the particular research tool patents at issue. This article reviews the Integra decision and its background, and outlines various factors that might be evaluated to provide an answer.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
This article highlights how copyright law in the United Kingdom differs from U.S. copyright law, and points out differences that may be crucial to entertainment and media businesses familiar with U.S law that are interested in operating in the United Kingdom or under UK law. The article also briefly addresses contrasts in UK and U.S. trademark law.
The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.
With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.
In Rockwell v. Despart, the New York Supreme Court, Third Department, recently revisited a recurring question: When may a landowner seek judicial removal of a covenant restricting use of her land?
Possession of real property is a matter of physical fact. Having the right or legal entitlement to possession is not "possession," possession is "the fact of having or holding property in one's power." That power means having physical dominion and control over the property.